Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Composition: Results Section for NCT03421379

Page standards status: Informative

version: 5; Last updated: 2025-09-14 18:30:51+0000

Profile: EvidenceReport

Artifact Description:

An evidence report summarizing the Results Section of a ClinicalTrials.gov record entry

url: https://fevir.net/resources/Composition/267224

identifier: FEvIR Object Identifier/267224, https://clinicaltrials.gov/NCT03421379 (use: official, ), FEvIR Linking Identifier/NCT03421379 Results Report

status: Final

type: EvidenceReport

category: ClinicalTrials.gov Study Results

date: 2025-09-14 18:30:51+0000

UseContexts

-CodeValue[x]
*UsageContextType program: ProgramClinicalTrials.gov

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter

name: NCT03421379_Results

title: Results Section for NCT03421379

custodian: Computable Publishing LLC

relatesTo

type: Derived From

target: https://clinicaltrials.gov/api/query/full_studies?expr=NCT03421379&max_rnk=1&fmt=JSON

relatesTo

type: Cite As

target:

Results Section for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267224. Revised 2025-09-14. Available at: https://fevir.net/resources/Composition/267224. Computable resource at: https://fevir.net/resources/Composition/267224#json.

Generated Narrative: PractitionerRole #PointOfContact

practitioner: Chief Medical Officer

organization: Eli Lilly and Company

Contacts

-Telecom
*ClinicalTrials.gov@lilly.com
*ph: 800-545-5979